Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Spruce Biosciences Inc (NQ: SPRB )

0.6874 -0.0126 (-1.80%)
Streaming Delayed Price Updated: 2:45 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Spruce Biosciences Inc

< Previous 1 2 Next >
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Inc. (NASDAQ: SPRB) Making Surprising Moves in Tuesday Session
Via Investor Brand Network
Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in the Jefferies London Healthcare Conference
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From Spruce Biosciences
Via Business Wire
Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Announces Acceptance of Abstract for Presentation at the Annual Meeting of the Endocrine Society (ENDO 2023)
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Appoints Percival Barretto-Ko to Board of Directors
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in the Jefferies Healthcare Conference
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Honored at CARES Foundation 15th Annual Everyone CARES Gala
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Present Findings on Retrospective Analysis of Completion Rates for CAH Studies at Pediatric Endocrine Society 2023 Annual Meeting
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in May Investor Conferences
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Announces $53.6 Million Private Placement Financing
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in the SVB Securities Global Biopharma Conference
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences (NASDAQ: SPRB) Enters Into Collaboration with Kaken Pharmaceutical to Develop Tildacerfont for CAH in Japan
Spruce Biosciences, Inc. (NASDAQ: SPRB) is engaged as a late-stage biopharmaceutical company, which is focused on the research, development and 
Via Spotlight Growth
Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in November Investor Conferences
From Spruce Biosciences, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.